Global Execution Strategies for a Neovascular AMD Clinical Trial

Discover how TFS HealthScience helped a biotech sponsor overcome the operational and regulatory challenges of launching a complex Phase III neovascular AMD clinical trial across 16 countries.

Neovascular age-related macular degeneration (AMD) is a leading cause of vision loss worldwide—especially in aging populations. Developing therapies for this condition requires large, global studies that involve strict eligibility criteria, specialized ophthalmic imaging, and regulatory precision across regions.

In this real-world case study, a U.S.-based sponsor partnered with TFS HealthScience to scale a pivotal Phase III neovascular AMD clinical trial—navigating logistical complexity, supporting older patient populations, and delivering results faster than expected.

Download the Case Study to Learn:

• How to Scale a Neovascular AMD Trial Globally
  Explore how feasibility planning, regulatory alignment, and local expertise enabled smooth study expansion into 16 new countries.
• Patient-Centric Design in Age-Related Trials
  See how flexible scheduling, travel support, and tailored site strategies improved retention in an older patient population.
• Proactive Data and Site Management Tactics
  Discover how early certification processes, consistent site communication, and adaptive data workflows supported high-quality execution and interim analysis readiness.
• The Power of Partnership in Complex Studies
  Learn how strong collaboration between sponsor, CRO, and investigative sites accelerated enrollment and ensured consistent progress—even in a highly complex therapeutic area.

If you’re planning or managing a neovascular AMD clinical trial, this case study provides strategic insight into overcoming common pitfalls in global ophthalmology research. With the right CRO partner, operational complexity can become a competitive advantage.

Learn more about our related services and resources:

TFS Ophthalmology